People | February 11, 2025
Peter Bains to replace Jonathan Hunt as CEO of Syngene
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
The transaction is expected to result in approximately $175 million to support further development of IMG-007
This is recommended for in-ovo vaccination of 18 to 19-day-old embryonated chicken eggs and one-day old chickens to protect against the virulent Marek’s disease
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
Genext Genomics can now offer comprehensive solutions that support the growth of India’s biotech ecosystem
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Subscribe To Our Newsletter & Stay Updated
